Variants impacting IL-1β are reported to influence risk of IA in patients with hematologic malignancies, and following solid organ transplant; the genes harboring risk variants include IL1A, IL1B, IL1RA, and IL1RN (Sainz et al., 2008; Wojtowicz et al., 2015a). This evidence concerns the gene IL1RN and hematologic disorder.